Skip to main content
SDGR logo

SDGR · Schrodinger, Inc.

Track SDGR — free
$22.93 -3.41 (-12.95%) At close · Nov 20
Market Cap
$1.72B
Shares
75.08M
Volume · Nov 20 1.88M Avg daily vol (3M) 2.06M

Price & Indicators

 

Key stats

Close
$22.93
Fri 20 Nov
Open
$25.82
Fri 20 Nov
Average volume, 30 days
1.7M
shares a session
Short interest
9.8M
13.0% of shares · 5.8 days to cover
Day range
$22.75$26.30
Open $25.82 Close $22.93
52-week closing range
$11.07$33.39
Close $22.93 31.3% under the high
Short volume, last session
36%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 4
Price history
Feb 2020 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 10
Investor event
ACV Growth Guided at 12 to 17%

Schrodinger expects ACV to increase 12 to 17% this year off of 198; Bunsen remains in beta and the company is seeing license growth. The hosted transition targets 75% hosted by 2028.

4 source passages
every part of that involves a chemical discovered by Schrodinger's platform, or I shouldn't say necessarily discovered, but influenced by Schrodinger's platform. So our ACV is expected to increase 12 to 17% this year off of 198. Again, Bunsen is still in beta. So we've announced our transaction with Bristol Myers, but it's still in beta. I think we're pleased with what it's done on license growth, but some of that growth is still to come. But as we get through this transition and the hosted percentage increases to a place We've targeted 75% by 2028. Open the document at this passage
Nov 4
Earnings call
Raises ACV and drug discovery guidance after 17% ACV growth

Schrodinger raised full-year 2026 ACV guidance to $222 to $232 million and drug discovery revenue guidance to $75 to $85 million after 17% third-quarter ACV growth.

4 source passages
Welcome to Schrodinger's conference call to review third quarter 2026 financial results. Third quarter ACV was $44.7 million, which represents 17% growth year-over-year We now expect full-year 2026 ACV to be in the range of $222 to $232 million We now expect drug discovery revenue to be in the range of $75 to $85 million Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 19%, but quarterly net loss widens

Schrodinger generated revenue of $64.5 million for the three months ended September 30, 2026, up 19% from $54.3 million, while net loss widened to $37.7 million from $32.8 million.

Revenue $64.49M ▲ 18.7% Net loss $37.71M Diluted EPS -$0.50
Read from the MD&A section
Source passage
We generated revenue of $64.5 million and $54.3 million during the three months ended September 30, 2026 and 2025, respectively, representing a year-over-year increase of 19%. Our net loss for the three months ended September 30, 2026 was $37.7 million and our net loss for the three months ended September 30, 2025 was $32.8 million. Open the document at this passage
Nov 4
Current report 8-K
Raises 2026 outlook and clarifies SGR-1505 study status

Schrödinger reported third-quarter ACV of $44.7 million, up 17%, and raised 2026 ACV guidance to $222 million to $232 million and drug discovery revenue guidance to $75 million to $85 million. It clarified that no SGR-1505 combination study had been initiated under its FDA-cleared protocol.

Financial results, Regulation FD disclosure
5 source passages
New York, November 4, 2026 – Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2026. ACV was $44.7 million, a 17% increase, and $214 million on a trailing four-quarter basis. ACV is expected to range from $222 million to $232 million, representing 12-17% growth over 2025, compared to the prior expectation of $218 million to $228 million or 10-15% growth over 2025. Drug discovery revenue is expected to range from $75 million to $85 million, compared to the prior expectation of $65 million to $75 million. The Company has in fact not initiated a combination study of SGR-1505 under its FDA-cleared protocol Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$269.20M
Trailing 12 months
Net income (TTM)
−$59.25M
Trailing 12 months
Revenue growth YoY
+18.7%
Year over year
Operating margin
-49.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$366.36M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.7%
Year over year · more shares
Price change (1Y)
+40.4%
Trailing year
Short interest
13.0%
Latest settlement · 5.8 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Schrodinger delivered 17% ACV growth, 19% total revenue growth and 49% hosted software revenue growth, raised full-year ACV and drug discovery revenue guidance, reduced operating expenses and ended the quarter with $373 million of cash, cash equivalents, restricted cash and marketable securities. Platform initiatives and the therapeutics portfolio advanced, while the main negatives were a wider net loss and equity-investment mark-to-market expense, lower software gross margin, operating cash outflow, temporary hosted-transition revenue pressure, limited milestone visibility and the lack of an initiated SGR-1505 combination study.

Bullish
  • + Full-year drug discovery revenue guidance was raised to $75 million–$85 million from $65 million–$75 million. new
Bearish
  • − Software gross margin declined to 75% from 77% due to the transition to hosted software licensing.
  • − The hosted-license transition temporarily reduces reported software revenue. new
  • − Future milestone timing has limited visibility despite the company's milestone track record. new
  • − An SGR-1505 combination study had not been initiated, and the company is exploring strategic opportunities to continue development. new
  • − Nine-month net cash used in operating activities was (96,482) thousand, compared with 29,992 thousand provided in the prior-year period. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +29%
above
Price vs 50-day avg −17%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 53%
mid-range
Momentum
relative strength
Strong
1-month return −4%
trailing
6-month return +53%
trailing
YTD return +28%
this year
Relative strength +63%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $28 › 200d $18 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +75 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.99% of shares out · ▼ -6.3% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
282 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Excellent
Revenue growth +23%
Y/Y
Gross margin 56%
contracting
EPS growth +45%
Y/Y
Free cash flow $12.5M
Balance sheet $230.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −43%
past year
ATR 11.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the Earnings Call filed Nov 4, 2026
full-year 2026
ACV Raised $222M – $232M
Aug 5, 2026 $218M – $228M changed to Nov 4, 2026 $222M – $232M
Drug discovery revenue Raised $75M – $85M
Aug 5, 2026 $65M – $75M changed to Nov 4, 2026 $75M – $85M
over the next three years
Drug discovery revenue $150M
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Hosted · by the end of 2028 75%
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
ACV excluding contribution · third quarter of 2026 $41M – $45M
Guided vs delivered · last 2 settled
Total revenue fiscal year ending December 31, 2022
guided $167M – $175M
$180.96M Beat +5.8%
Total revenue fiscal year ending December 31, 2021
guided $124M – $134M
$137.93M Beat +6.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+29% Bullish
Price vs 50-day avg
−17% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
53% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $28 › 200d $18 — 50d above 200d
Institutional flow Accumulating
+21% holders QoQ · +75 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.99% of shares out · ▼ -6.3% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
282 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11 Now $23 · 53% Range high $33
vs 200-day avg +29% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
ACV $44.7M third quarter 2026 —
Adjusted EBITDA non-GAAP -$85.47M Nine Months Ended September 30, 2026 —
Cash, cash equivalents, restricted cash and marketable securities $373M September 30, 2026 —
Hosted software revenue as percent of total software revenue 32% trailing four-quarter basis —
Annual contract value (ACV) non-GAAP $29.6M the three months ended June 30, 2026 filing —
Software gross margin 71% Q2 2026 —
Software products and services gross margin 71% the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SDGR
Schrodinger, Inc.
this stock
$1.72B +28.2% +23.3% — 13.0%
VEEV
Veeva Systems Inc
$43.10B +19.3% +28.1% 43.6 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.50B +67.8% +28.2% 34.2 5.8%
TEM
Tempus AI, Inc.
$9.86B -8.5% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
282
% held
84.2%
Net QoQ
-1.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
204
View
Short & Settlement
Short Interest Falling
Shares short
9.8M
Days to cover
5.8d
Change
-652.0K sh
View
Short Volume
Short vol %
36%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
18
Value
$451
As of
Oct 15, 2026
View
Off-Exchange
Off-exchange %
42.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$255.9M
Net income (FY)
$-103.3M
EPS diluted
$-1.41
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
20

Schrodinger expects ACV to increase 12 to 17% this year off of 198; Bunsen remains in beta and the company is seeing license growth. The hosted transition targets 75% hosted by 2028.

View
Proposed Sales
Value
$954.2K
Shares
32.0K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Schrödinger Reports Third Quarter…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
SDGR -22.4% -3.7% +53.5% -15.5% +28.2%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -13.8% +5.6% +62.7% -6.8% +27.1%
Key facts CIK 1490978 CUSIP 80810D103 13F (30d) 271 filings 242 filers Visit website Investor relations